FOLFIRI+cetuximab

Phase 3Monoclonal antibody

FOLFIRI+cetuximab is one of 53 small molecule programs targeting Colorectal Cancer Metastatic. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Colorectal Cancer MetastaticNot yet recruiting

Colorectal CancerRecruiting

Colorectal Cancer MetastaticPhase 3

Not yet recruiting

Colorectal CancerPhase 2

Recruiting

Competition

Competitive Landscape

268 competitors in Colorectal Cancer

#DrugCompanyPhaseTrials

Camptosar

Pfizer

Phase 3

34 2

Keytruda

Merck & Co.

Phase 3

25 3

Fudr

Pfizer

Phase 3

16 4

Tyvyt

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3

8 5

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

3 6

Botensilimab

AAgenus Inc.

Phase 3

10 7

5-Fu

TToray Industries, Inc

Phase 3

3 8

Cadonilimab

SShanghai Pharmaceuticals Holding Co., Ltd

Phase 3

2 9

BL-M07D1

SSichuan Baili Pharmaceutical Co., Ltd.

Phase 3

1 10

FOLFIRI+cetuximab

NNational Cancer Institute, Naples

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2031

Phase 3Not yet recruiting

Colorectal Cancer Metastatic

NCT07004413

Clinical

Trials by Indication[1]

Colorectal Cancer1 trial

Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients

Recruiting·NNational Cancer Institute, Naples·Phase 2·NCT03874026·34 enrolled

Colorectal Cancer Metastatic1 trial

Randomized Study to Compare First-line Treatment With Either Continuous or Intermittent Cetuximab Plus FOLFIRI in Patients With RAS/BRAF-wild-type Metastatic Colorectal Cancer (mCRC): AIO-KRK-0524 / FIRE-11

Not yet recruiting·CCharite University, Berlin, Germany·Phase 3·NCT07004413·267 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for FOLFIRI+cetuximab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — FOLFIRI+cetuximab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for FOLFIRI+cetuximab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Cancer Institute, Naples company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 3[1]
Company: NNational Cancer Institute, Naples

FOLFIRI+cetuximab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2031

Trials by Indication[1]

Colorectal Cancer1 trial

Colorectal Cancer Metastatic1 trial

References

Drug Info

Quick Facts

Related News